Exploring genetic factors in pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to screen first-degree family members of individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF) for early signs of lung fibrosis. The researchers will investigate genetic factors and environmental exposures that may contribute to the development of pulmonary fibrosis. By enrolling both patients with pulmonary fibrosis and their family members, the study seeks to identify genetic loci associated with this condition. Blood samples and questionnaires will be utilized to gather necessary data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age at least 18 years old
* Family member diagnosed with IPF

Exclusion Criteria:

\- No family member with IPF

Where it's running

• University of Colorado Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting

Study contacts

• Principal investigator: David A Schwartz, MD — University of Colorado, Denver
• Study coordinator: Rachel Warren
• Email: rachel.warren@cuanschutz.edu
• Phone: 303-724-8569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nerandomilast in IPF and Progressive Fibrosis: Real-World Data

  This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.

  Recruiting at 4 sites Tel Aviv Medical Center · Ashkelon and 3 other locations · NCT07919015

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Finger vs. Earlobe Pulse Oximetry During a 6-Minute Walk Test in ILD

  This study tests whether finger or earlobe pulse oximetry gives the same oxygen saturation readings during a 6-minute walk in people with interstitial lung disease.

  Recruiting Hospital de Granollers · Granollers, Spain · NCT07723872

• Biomarker clues for COPD, IPF, and lung cancer

  This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.

  Recruiting Fondazione Don Carlo Gnocchi ETS · Milan, Milan · NCT07707245

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

• AZD8965 in IPF: see if three doses help IPF patients

  This Phase IIb study tests three doses of AZD8965 against placebo in people with idiopathic pulmonary fibrosis, including those who are and aren’t on antifibrotic therapy.

  Recruiting at 103 sites Phase 2 AstraZeneca · Birmingham, Alabama and 197 other locations · NCT07652658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.